BioCryst Pharmaceuticals: all 74 studies

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy ParticipantsRecruitingNCT07635095Phase 1
• A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationNCT07204938Phase 3
• A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725RecruitingNCT06539507Phase 1
• Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesEnrolling by invitationNCT04933721Phase 3
• Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaTerminatedNCT05741346Phase 2Results posted
• A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedNCT05695248Phase 1/2Results posted
• Berotralstat Treatment in Children With Hereditary AngioedemaActive, not recruitingNCT05453968Phase 3Results posted
• Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)TerminatedNCT05162066Phase 2Results posted
• BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyTerminatedNCT05116787Phase 2Results posted
• BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTerminatedNCT05116774Phase 2Results posted
• A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedNCT04702568Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCompletedNCT03873116Phase 3Results posted
• A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430CompletedNCT03800173Phase 1Results posted
• Phase III Study of Edasalonexent in Boys With Duchenne Muscular DystrophyCompletedNCT03703882Phase 3Results posted
• Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAECompletedNCT03485911Phase 3Results posted
• A Long Term Safety Study of BCX7353 in Hereditary AngioedemaCompletedNCT03472040Phase 2/3Results posted
• Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaCompletedNCT03240133Phase 2Results posted
• Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCompletedNCT02870972Phase 2Results posted
• Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaCompletedNCT02635724Phase 3Results posted
• Phase 1/2 Study in Boys With Duchenne Muscular DystrophyCompletedNCT02439216Phase 1/2Results posted
• Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaCompletedNCT02369159Phase 3Results posted
• 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCompletedNCT02303626Phase 2/3Results posted
• A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaTerminatedNCT00958776Phase 3Results posted
• Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected InfluenzaCompletedNCT00957996Phase 3Results posted
• A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute InfluenzaCompletedNCT00705406Phase 2Results posted
• Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaTerminatedNCT00610935Phase 3Results posted
• Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening InfluenzaCompletedNCT00453999Phase 2Results posted
• Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.CompletedNCT00419263Phase 2Results posted
• A Study of Avoralstat In Participants With Diabetic Macular EdemaTerminatedNCT07228559Phase 1
• A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingNCT06842823Phase 3
• A Study of STAR-0310 in Healthy Adult ParticipantsActive, not recruitingNCT06782477Phase 1
• Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT06100900Phase 1
• A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingNCT06007677Phase 2
• A Study of STAR-0215 in Healthy Adult ParticipantsCompletedNCT05477160Phase 1
• Study of Edasalonexent With Midazolam and Deflazacort in Healthy SubjectsCompletedNCT04543370Phase 1
• Oral Berotralstat Expanded Access ProgramApproved for marketingNCT04428632
• First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHCompletedNCT04330534Phase 1/2
• An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular DystrophyTerminatedNCT03917719Phase 3
• A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19TerminatedNCT03891420Phase 1
• A Relative Bioavailability Study of Two Formulations of BCX7353CompletedNCT03202784Phase 1
• A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCompletedNCT03136237Phase 1
• An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe SubstratesCompletedNCT02819102Phase 1
• Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaTerminatedNCT02670720Phase 3
• A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With HypercholesterolemiaCompletedNCT02608697Phase 2
• First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersCompletedNCT02448264Phase 1
• A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy SubjectsCompletedNCT02374047Phase 1
• A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430CompletedNCT02319772Phase 1
• Study to Determine How BCX4161 is Metabolized and Eliminated by the BodyCompletedNCT02218294Phase 1
• A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161CompletedNCT02125162Phase 1
• Pilot Study To Assess CAT-2003 in Patients With ChylomicronemiaCompletedNCT02098278Phase 2
• Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAECompletedNCT01984788Phase 2
• Pilot Study To Assess CAT-2003 in Patients With Severe HypertriglyceridemiaCompletedNCT01968720Phase 2
• Pilot Study To Assess CAT-2003 in Patients With HyperlipidemiaCompletedNCT01912560Phase 2
• A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003CompletedNCT01725594Phase 1
• A Study of CAT-1004 Biomarkers in Healthy SubjectsCompletedNCT01670773Phase 1
• A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 DiabetesCompletedNCT01511900Phase 1
• Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult VolunteersCompletedNCT01440166Phase 1
• A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal InsufficiencyCompletedNCT01407874Phase 2
• Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to AllopurinolCompletedNCT01265264Phase 2
• A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.WithdrawnNCT01224795Phase 3
• Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/GoutCompletedNCT01129648Phase 2
• Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With GoutCompletedNCT00985127Phase 2
• Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00640523Phase 2
• Forodesine in the Treatment of Cutaneous T-Cell LymphomaCompletedNCT00501735Phase 2
• Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaWithdrawnNCT00486980Phase 3
• Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensTerminatedNCT00419081Phase 2
• Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic LeukemiaCompletedNCT00289562Phase 1/2
• Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT00289549Phase 2
• Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaCompletedNCT00098332Phase 1
• Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell LeukemiaCompletedNCT00095381Phase 2
• BCX-1777 in Treating Patients With Refractory CancerCompletedNCT00073944Phase 1
• BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell LymphomaCompletedNCT00061880Phase 1/2
• Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or LymphomasCompletedNCT00035022Phase 1/2
• A Study of Peldesine (BCX-34) in HIV-Infected PatientsCompletedNCT00002237Phase 1

← BioCryst Pharmaceuticals overview and focus areas